Should I buy or sell Cellebrite DI stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLBT shares. View CLBT analyst ratings or view top-rated stocks .

What is Cellebrite DI's stock price target for 2024?

3 brokers have issued 1 year target prices for Cellebrite DI's shares. Their CLBT share price targets range from $6.75 to $11.00. On average, they predict the company's stock price to reach $9.35 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts price targets for CLBT or view top-rated stocks among Wall Street analysts .

How have CLBT shares performed in 2023?

Cellebrite DI's stock was trading at $4.36 at the start of the year. Since then, CLBT stock has increased by 92.0% and is now trading at $8.37. View the best growth stocks for 2023 here .

When is Cellebrite DI's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our CLBT earnings forecast .

How were Cellebrite DI's earnings last quarter?

Cellebrite DI Ltd. (NASDAQ:CLBT) posted its quarterly earnings results on Tuesday, November, 14th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.08. The firm had revenue of $84.20 million for the quarter, compared to analysts' expectations of $82.13 million. Cellebrite DI had a negative net margin of 19.40% and a positive trailing twelve-month return on equity of 119.62%. The company's quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the firm posted ($0.01) earnings per share.

What ETFs hold Cellebrite DI's stock?

ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) . BlueStar Israel Technology ETF (ITEQ) .

Who are Cellebrite DI's major shareholders?

Cellebrite DI's stock is owned by many different institutional and retail investors. Top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (3.38%), Phoenix Holdings Ltd. (3.09%), Greenhaven Road Investment Management L.P. (1.61%), Morgan Stanley (1.20%), Acadian Asset Management LLC (0.85%) and Connor Clark & Lunn Investment Management Ltd. (0.38%).

How do I buy shares of Cellebrite DI?

Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Cellebrite DI Stock Price, News & Analysis (NASDAQ:CLBT)

$8.49

+0.12 (+1.43%)

(As of 09:39 AM ET)

Compare

Today's Range: $8.41
▼
$8.51
50-Day Range: $6.45
▼
$8.50
52-Week Range: $3.96
▼
$8.60

Volume: 23,357 shs
Average Volume: 327,690 shs
Market Capitalization: $1.68 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.35

Cellebrite DI MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 11.7% Upside
$9.35 Price Target
Short Interest: Bearish
4.72% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.76
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -8.00%
From $0.25 to $0.23 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Business Services Sector

282nd out of 314 stocks

Prepackaged Software Industry

179th out of 203 stocks

2.5

Analyst's Opinion

Consensus Rating
Cellebrite DI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.35, Cellebrite DI has a forecasted upside of 11.7% from its current price of $8.37.
Amount of Analyst Coverage
Cellebrite DI has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.72% of the float of Cellebrite DI has been sold short.
Short Interest Ratio / Days to Cover
Cellebrite DI has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Cellebrite DI has recently increased by 2.56%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cellebrite DI does not currently pay a dividend.
Dividend Growth
Cellebrite DI does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLBT.

3.8

News and Social Media Coverage

News Sentiment
Cellebrite DI has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Business Services companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Cellebrite DI this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for CLBT on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.
MarketBeat Follows
9 people have added Cellebrite DI to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cellebrite DI insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Cellebrite DI is held by insiders.
Percentage Held by Institutions
Only 21.80% of the stock of Cellebrite DI is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cellebrite DI are expected to decrease by -8.00% in the coming year, from $0.25 to $0.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cellebrite DI is -27.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cellebrite DI is -27.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Cellebrite DI has a PEG Ratio of 0.69. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Cellebrite DI has a P/B Ratio of 44.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cellebrite DI Stock (NASDAQ:CLBT)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the United States, and the Asia-Pacific. Its DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Cellebrite Pathfinder helps investigators reach conclusions faster through automated data ingestion, normalization, consolidation, and visualization of a suspects' journey; CryptoCurrency Investigative Solutions, which analyze blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets and transactions; and OSINT Investigate solution used to search, resolve, and enrich identifiers in open sources. In addition, the company provides Cellebrite Guardian, a cloud-based digital investigative data and evidence management SaaS solution that allows users to manage, store, share, and review investigative data and evidence from intake to creation of a final report; and Commander solution that enables collaboration across investigation functions to reduce manual processes. It serves federal and state and local agencies, as well as enterprise companies and service providers. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. is a subsidiary of Sun Corporation.

CLBT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLBT Stock News Headlines

November 28, 2023 | finanznachrichten.de

Cellebrite DI Ltd: Cellebrite Showcases Innovations in Digital Intelligence at Milipol 2023

November 28, 2023 | finance.yahoo.com

Cellebrite Showcases Innovations in Digital Intelligence at Milipol 2023

November 29, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.

November 27, 2023 | seekingalpha.com

Cellebrite: The Moat Is Widening

November 24, 2023 | americanbankingnews.com

Cellebrite DI (NASDAQ:CLBT) Sets New 12-Month High at $8.38

November 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Technology Stocks: Cellebrite DI (CLBT), Nvidia (NVDA)

November 17, 2023 | msn.com

Earnings Estimates Moving Higher for Cellebrite DI Ltd. (CLBT): Time to Buy?

November 16, 2023 | msn.com

Is Cellebrite DI Ltd. (CLBT) Stock Outpacing Its Business Services Peers This Year?

November 29, 2023 | Edge On The Street (Ad)

An Unusual Way to Invest in Gold

November 15, 2023 | stockhouse.com

Cellebrite's 2024 Industry Trends Survey Reveals Urgent Digital Challenges in Law Enforcement

November 15, 2023 | finance.yahoo.com

Cellebrite DI Ltd. (NASDAQ:CLBT) Q3 2023 Earnings Call Transcript

November 14, 2023 | finanznachrichten.de

Cellebrite DI Ltd: Cellebrite Announces Third-Quarter 2023 Results

November 14, 2023 | benzinga.com

Cellebrite DI: Q3 Earnings Insights

November 14, 2023 | finance.yahoo.com

Cellebrite Continues Global Growth with Appointment of First Global Chief Revenue Officer, Marcus Jewell

November 14, 2023 | finance.yahoo.com

Cellebrite Announces Third-Quarter 2023 Results

November 13, 2023 | finance.yahoo.com

Cellebrite’s 2024 Industry Trends Survey Reveals Urgent Digital Challenges in Law Enforcement

November 12, 2023 | finance.yahoo.com

Cellebrite DI Ltd.'s (NASDAQ:CLBT) Intrinsic Value Is Potentially 64% Above Its Share Price

November 9, 2023 | finance.yahoo.com

Mobile Ultra: Advancing Digital Investigations in the Age of Evolving Technology

November 8, 2023 | finanznachrichten.de

Cellebrite DI Ltd: Cellebrite Equips Investigators with Next Generation Cloud-Based Solution

November 8, 2023 | finance.yahoo.com

Cellebrite Equips Investigators with Next Generation Cloud-Based Solution

November 1, 2023 | finance.yahoo.com

Should You Hold Cellebrite DI Ltd. (CLBT)?

October 24, 2023 | finance.yahoo.com

Cellebrite Furthers Global Commitment and Partnerships with Global Law Enforcement Community at International Association of Chiefs of Police Conference

October 18, 2023 | finance.yahoo.com

Cellebrite Elevates Digital Forensics Training with New MyCellebrite Learning Hub

October 18, 2023 | finance.yahoo.com

Cellebrite Elevates Digital Forensics Training with New MyCellebrite Learning Hub

October 13, 2023 | markets.businessinsider.com

Cellebrite DI (CLBT) Receives a Buy from Craig-Hallum

October 10, 2023 | finance.yahoo.com

Cellebrite to Report Third-Quarter 2023 Financial Results on November 14, 2023

October 10, 2023 | finance.yahoo.com

Cellebrite Experts to Moderate Human Trafficking Panel, Present on Digital Intelligence at International Association of Chiefs of Police (IACP) Expo and Conference

See More Headlines

Receive CLBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellebrite DI and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Prepackaged software
Sub-Industry: N/A
Sector: Business Services
Current Symbol: NASDAQ:CLBT
CUSIP: N/A
CIK: 1854587
Web: www.cellebrite.com
Phone: 972-73-394-8000
Fax: 972-3924-7104
Employees: 1,005
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.35
High Stock Price Target: $11.00
Low Stock Price Target: $6.75
Potential Upside/Downside: +11.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 33.48
P/E Growth: 0.69
Net Income: $120.81 million
Net Margins: -19.40%
Pretax Margin: -17.68%
Return on Equity: 119.62%
Return on Assets: 11.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.65
Quick Ratio: 1.60

Sales & Book Value

Annual Sales: $270.65 million
Price / Sales: 6.10
Cash Flow: $0.09 per share
Price / Cash Flow: 93.58
Book Value: $0.39 per share
Price / Book: 21.46

Miscellaneous

Outstanding Shares: 197,370,000
Free Float: 186,118,000
Market Cap: $1.65 billion
Optionable: Optionable
Beta: 1.31

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Yossi Carmil (Age 56)
Founder, CEO & Director
Comp: $946k
Ms. Dana Gerner (Age 56)
Chief Financial Officer
Comp: $477k
Mr. Leeor Ben-Peretz (Age 47)
Chief Strategy Officer
Comp: $416k
Mr. Marque Teegardin (Age 57)
President of Cellebrite Americas - Sales Management
Comp: $868.71k
Mr. Thomas E. Hogan (Age 64)
Executive Chairman
Mr. Arnon Zilberman
Executive Vice President of Information Systems & Operations
Mr. Ronnen Armon (Age 60)
Chief Products & Technologies Officer
Andrew Kramer
Vice President of Investor Relations
Ms. Ayala Berler Shapira
General Counsel
Ms. Lisa Cole (Age 49)
Chief Marketing Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLBT Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellebrite DI stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellebrite DI in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLBT shares.
View CLBT analyst ratings or view top-rated stocks.
What is Cellebrite DI's stock price target for 2024?: 3 brokers have issued 1 year target prices for Cellebrite DI's shares. Their CLBT share price targets range from $6.75 to $11.00. On average, they predict the company's stock price to reach $9.35 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts price targets for CLBT or view top-rated stocks among Wall Street analysts.
How have CLBT shares performed in 2023?: Cellebrite DI's stock was trading at $4.36 at the start of the year. Since then, CLBT stock has increased by 92.0% and is now trading at $8.37.
View the best growth stocks for 2023 here.
When is Cellebrite DI's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our CLBT earnings forecast.

How were Cellebrite DI's earnings last quarter?: Cellebrite DI Ltd. (NASDAQ:CLBT) posted its quarterly earnings results on Tuesday, November, 14th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.08. The firm had revenue of $84.20 million for the quarter, compared to analysts' expectations of $82.13 million. Cellebrite DI had a negative net margin of 19.40% and a positive trailing twelve-month return on equity of 119.62%. The company's quarterly revenue was up 17.4% on a year-over-year basis. During the same period last year, the firm posted ($0.01) earnings per share.
What ETFs hold Cellebrite DI's stock?: ETFs with the largest weight of Cellebrite DI (NASDAQ:CLBT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).BlueStar Israel Technology ETF (ITEQ).
Who are Cellebrite DI's major shareholders?: Cellebrite DI's stock is owned by many different institutional and retail investors. Top institutional shareholders include Clal Insurance Enterprises Holdings Ltd (3.38%), Phoenix Holdings Ltd. (3.09%), Greenhaven Road Investment Management L.P. (1.61%), Morgan Stanley (1.20%), Acadian Asset Management LLC (0.85%) and Connor Clark & Lunn Investment Management Ltd. (0.38%).
How do I buy shares of Cellebrite DI?: Shares of CLBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLBT) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial